Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Harbor Investment Advisory LLC

Harbor Investment Advisory LLC grew its stake in Novo Nordisk A/S (NYSE:NVO) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,800 shares of the company’s stock after buying an additional 153 shares during the period. Harbor Investment Advisory LLC’s holdings in Novo Nordisk A/S were worth $155,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NVO. International Assets Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after buying an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. Marshall Wace LLP boosted its holdings in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.5 %

NVO stock opened at $80.59 on Thursday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The stock has a market capitalization of $361.65 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a fifty day moving average of $96.63 and a 200-day moving average of $116.04.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.